CVS Health (CVS) Reiterated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $110.00 price target on CVS Health (NYSE: CVS).

The analyst commented, "We've analyzed 2027 Stars cutpoints & our early call is optimistic about the early October 2026 release of 2027 Stars. HUM's accelerated Stars program investments could likely be enough as only 47% of 4-Star thresholds got harder in 2027 Stars vs. 2026 Stars, and we continue to believe CAHPS-related concerns around UNH are misplaced. Overall, the lighter-than-expected movement in cutpoints is another reason, in our view, to underwrite the MA margin & pricing cycle (HUM, CVS, UNH, ELV, CNC, MOH) through to target margins."

For an analyst ratings summary and ratings history on CVS Health click here. For more ratings news on CVS Health click here.

Shares of CVS Health closed at $95.29 yesterday.

You May Also Be Interested In

• MannKind (MNKD) Reiterated at Overweight by Cantor Fitzgerald on Positive MNKD-201 Ph1 Data
• Jersey Mike's Subs (JMKE) PT Raised to $29 at Guggenheim
• Humana (HUM) Reiterated at Neutral by Cantor Fitzgerald